We evaluated the effect of proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) on the efficacy and safety of dasatinib for chronic-phase chronic myeloid leukemia (CP-CML). Retrospective analyses were performed for patients with CP-CML who received dasatinib at seven hospitals between April 2009 and December 2016. Seventy-three patients were identified, 16 of whom received PPIs or H2RAs concurrently with dasatinib. Major molecular response at 12 months was observed in 13 of 13 patients (100%) with concurrent PPIs or H2RAs (combination group), and in 23 of 51 patients (45.1%) who received only dasatinib (dasatinib-alone group; P < 0.001). Deep molecular response at 12 months was observed in four of six patients (66.7%) in the combination group, and seven of 38 patients (18.4%) in the dasatinib-alone group (P = 0.027). Dasatinib chemotherapy was stopped after 18 months for 25 patients (43.9%) from the dasatinib-alone group, but for none from the combination group. Combination treatment with PPIs or H2RAs did not reduce the efficacy of dasatinib. PPIs and H2RAs reduce the incidence of dasatinib discontinuation due to adverse events and increase the efficacy of dasatinib chemotherapy for patients.

中文翻译：

---

质子泵抑制剂和H2受体拮抗剂对dasatinib在慢性粒细胞白血病患者中的疗效和安全性的影响。

我们评估了质子泵抑制剂（PPI）和H2受体拮抗剂（H2RAs）对达沙替尼治疗慢性慢性粒细胞白血病（CP-CML）的有效性和安全性的影响。回顾性分析了2009年4月至2016年12月在七家医院接受过dasatinib的CP-CML患者。确定了73例患者，其中16例与dasatinib同时接受PPI或H2RA。在13例同时发生PPI或H2RA的患者中有13例（100％）在12个月时出现了主要的分子反应（在联合治疗组中），在51例中只有23例（45.1％）的患者中有23例（45.1％）观察到了（P <0.001 ）。联合治疗组的6名患者中有4名（66.7％）在12个月时观察到了深层分子反应，而在达沙替尼组中38名患者中有7名（18.4％）观察到（P = 0.027）。18个月后，仅达沙替尼组的25例患者（43.9％）停止了达沙替尼化疗，但联合组中无一例。PPI或H2RA的联合治疗并未降低达沙替尼的疗效。PPI和H2RA减少了因不良事件而终止dasatinib的发生率，并提高了dasatinib化疗对患者的疗效。